Monthly Safety Labeling Changes includes 48 products with revisions to Prescribing Information.
Labeling, Approval Order, and Summary of Safety and Effectiveness for NeuRx DPS?, Diaphragm Pacing System (H100006).
Belotero Balance is a transparent hyaluronic acid gel that is injected into facial tissue to smooth wrinkles and folds, especially around the nose and mouth. Hyaluronic acid is a protective, lubricating and binding gel that is produced naturally by the...
Labeling, Approval Order, and Summary of Safety and Effectiveness for BELOTERO Balance (P090016).
Weeks after missing a self-imposed deadline to respond to Institute of Medicine (IOM) recommendations on the 510(k) process, CDRH Director Jeffrey Shuren told senators at a Tuesday hearing he’s unsure when the agency’s response will see daylight.
The device industry and the FDA are closer to an agreement on reauthorizing the Medical Device User Fee Amendments Act (MDUFMA), but chances are slim that the agency will meet the Jan. 15 goal to delivery that agreement to Congress.
Industry provided a response and counter-proposal to the proposal offered by the Agency on August 24, 2011. Industry reiterated that their intent from the beginning of these negotiations has been to achieve a process that is efficient and ultimately...
ROCHESTER, N.Y.--(BUSINESS WIRE)--Carestream has received a clearance letter from the U.S. Food and Drug Administration (FDA) for the use of its Vue Motion medical image viewer with mobile devices such as Apple iPads in the United States. The zero-footprint, Web-based viewer...
LEXINGTON, Ky.--(BUSINESS WIRE)--MedPro Safety Products, Inc. (OTCBB: MPSP), a leading developer of transformational technologies that enable safer medication delivery and blood collection, today announced that it has passed its ISO 13485 recertification audit.
Positive Clinical Study Results for BSP's HyperQ Technology will be reported in American Journal of CardiologyNovember 15, 2011 4:56 am | News | Comments
Tel - Aviv, November 14, 2011 - BSP Biological Signal Processing Ltd. (BSP) (TASE: BSP), which develops and manufactures products for the non-invasive, accurate diagnosis of Coronary Artery Disease (CAD), recently announced the successful completion of a comprehensive clinical research study...
Washington, D.C. â€“ Over 100,000 people throughout the country have signed a petition urging the FDA to issue clear and reasonable guidance Â for development of an artificial pancreas (AP), the most revolutionary advance in treating type 1 diabetes (T1D) since the discovery of insulin.
Product marketed as dietary supplement contains sulfoaildenafil, which may interact with nitrates found in some prescription drugs and lower blood pressure to dangerous levels.
The FDA proposes to streamline device clinical trials in a pair of draft guidances outlining requirements for early feasibility studies and explaining when a trial can begin even when there are outstanding issues with an Investigational Device Exemption (IDE) submission.
Medical device industry reps and FDA officials negotiating the next user fee authorization are behind schedule and want to accelerate their progress, but those meetings remain acrimonious and the parties are still far apart on major issues.
Draft Guidance for Industry, Clinical Investigators, Institutional Review Boards, and Food and Drug Administration Staff - FDA Decisions for Investigational Device Exemption (...November 10, 2011 3:31 am | by U.S. Food & Drug Administration | News | Comments
This guidance document has been developed to promote the initiation of clinical investigations to evaluate medical devices under FDA?s Investigational Device Exemptions (IDE) regulations, Title 21 Code of Federal Regulations (CFR) Part 812.
Draft Guidance for Industry and Food and Drug Administration Staff - Investigational Device Exemptions (IDE) for Early Feasibility Medical Device Clinical Studies, Including C...November 10, 2011 3:30 am | by U.S. Food & Drug Administration | News | Comments
This document is intended to provide guidance to FDA staff, clinicians, clinical innovators, and industry on the development and review of Investigational Device Exemption (IDE) applications for early feasibility studies of significant risk devices.
Potential for patient falls or unanticipated patient movement, which may result in serious injury or death.
The ACCORD Lipid trial found no significant difference in the risk of a major adverse cardiac event between group treated with fenofibrate plus simvastatin compared with simvastatin alone.
This webpage gives tips for safely disposing needles and other sharp devices that are used outside of health care settings. Patients and caregivers should keep these tips in mind when at home, at work, and while traveling.
NEW YORK, Nov. 8, 2011 /PRNewswire/ --Â A group of states and vendors focused on eliminating the barriers to sharing electronic health records (EHRs) today issued a set of technical specifications to standardize connections between healthcare providers, health information exchanges (HIEs)...
Industry's October 6, 2011 proposal allows applicants 15 days to draft pre-submission meeting minutes followed by 15 days for FDA to provide edits to the applicant?s draft minutes and 15 days for the applicant to indicate disagreement with how a...
Public Workshop - Bridging the IDEAL and TPLC Approaches for Evidence Development for Surgical Medical Devices and Procedures, December 2, 2011November 7, 2011 4:30 am | by U.S. Food & Drug Administration | News | Comments
The purpose of the public workshop is to provide a forum for discussion among FDA, governmental agencies, academia, physicians and various stakeholders to f urther refine and advance the IDEAL initiative (Idea Development Exploration, Assessment and...
Failure to adequately ventilate may lead to hypoxia or hypercarbia, which may result in serious neurological injury or death.
U.S. Senators, Clinicians and People with Type 1 Diabetes Urge FDA to Issue Clear and Reasonable Guidance on Artificial PancreasNovember 2, 2011 7:32 pm | News | Comments
Washington, D.C. â€“ U.S. Senators, clinical experts, and people with type 1 diabetes (T1D) today urged the Food and Drug Administration (FDA) to issue clear and reasonable guidance on the artificial pancreas (AP) that avoids unnecessary delays in development and delivery of a medical technology...
Meeting Materials for National Mammography Quality Assurance Advisory Committee meeting on November 4, 2011November 2, 2011 4:30 am | by U.S. Food & Drug Administration | News | Comments
The National Mammography Quality Assurance Advisory Committee advises on developing appropriate quality standards and regulations for the use of mammography facilities.